SPIDVAC - Improved control of priority animal diseases: Novel vaccines and companion diagnostic tests for African horse sickness, peste des petits ruminants and foot-and-mouth disease

SPIDVAC - 改善重点动物疾病的控制：针对非洲马病、小反刍兽疫和口蹄疫的新型疫苗和伴随诊断测试

• 批准号: 10043719
• 金额: $ 53.33万
• 依托单位: UNIVERSITY OF SURREY
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10043719
• 关键词: SPIDVAC; Improved; control; priority; animal

Current vaccines for African horse sickness (AHS), peste des petits ruminants (PPR) and foot-and-mouth disease (FMD) have critical shortcomings that leave the European Union vulnerable to these category A transboundary animal diseases, but control strategies that rely on culling alone are increasingly rejected by the public. At the same time, the risk of an introduction of AHS, PPR or FMD into Europe is growing, driven by climate change, global trade and long-distance travel. Innovative vaccines and companion diagnostics that are grounded in an increased knowledge of pathogenesis and immunity are urgently required to improve the capacity to prevent introductions and contain outbreaks, which are a major threat to European agriculture. The SPIDVAC (Safe Priority Infectious Diseases VACcines) consortium consists of 13 partners from Germany, France, Spain, the United Kingdom, the Netherlands, South Africa and Senegal, who will develop innovative vaccines against AHS, PPR and FMD and evaluate their capabilities in vitro, demonstrate the safety and efficacy of the candidate vaccines in small-animal models and in the target species and develop companion diagnostic to reliably differentiate between infected and vaccinated animals (DIVA). In addition, the project will increase knowledge on the mechanisms of infection, virulence and immunity and study the acceptability of vaccines for stakeholders in endemic areas. The consortium includes industry partners for veterinary vaccines and diagnostic tools, who will ensure the technological readiness and market relevance of the newly developed tools, which will help policy makers, veterinary services and business operators reduce the burden of infectious animal diseases, contribute to a sustainable livestock industry and promote public and animal health from farm to fork.

目前针对非洲马瘟 (AHS)、小反刍兽疫 (PPR) 和口蹄疫 (FMD) 的疫苗存在严重缺陷，使欧盟容易受到这些 A 类跨境动物疾病的影响，但控制策略依赖于仅仅扑杀就越来越受到公众的排斥。与此同时，在气候变化、全球贸易和长途旅行的推动下，AHS、PPR 或 FMD 进入欧洲的风险正在增加。迫切需要以增加发病机制和免疫知识为基础的创新疫苗和伴随诊断，以提高防止传入和遏制疫情爆发的能力，这是欧洲农业的主要威胁。 SPIDVAC（安全优先传染病疫苗）联盟由来自德国、法国、西班牙、英国、荷兰、南非和塞内加尔的 13 个合作伙伴组成，他们将开发针对 AHS、PPR 和 FMD 的创新疫苗，并评估其体外能力，证明候选疫苗在小动物模型和目标物种中的安全性和有效性，并开发伴随诊断以可靠地区分受感染的动物和已接种疫苗的动物（DIVA）。此外，该项目还将增加对感染、毒力和免疫机制的了解，并研究流行地区利益相关者对疫苗的可接受性。该联盟包括兽用疫苗和诊断工具的行业合作伙伴，他们将确保新开发工具的技术准备度和市场相关性，这将帮助政策制定者、兽医服务和企业经营者减轻传染性动物疾病的负担，为可持续发展做出贡献畜牧业，促进从农场到餐桌的公众和动物健康。